ELAC2 was the first identified prostate cancer susceptibility gene (Tavtigian et al, 2001) and encodes an RNase Z enzyme, which belongs to the metallo‐β‐lactamase superfamily of proteins found to process the 3′ ends of tRNAs (Takaku et al, 2003; Brzezniak et al, 2011; Lopez Sanchez et al, 2011). This evidence concerns the gene ELAC2 and prostate carcinoma.